AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
Abstract
:1. Introduction
2. Results
2.1. Comparison of NOXA Induction across Cell Lines
2.2. AT101 Induces NOXA in Carcinoma through Ca2+-Dependent ER Stress
2.3. AT101 Sensitizes Carcinoma Cells to Other BH3 Mimetics through NOXA
2.4. AT101 Is Comparable to Direct MCL1 Inhibitor AZD5991
2.5. AT101 Promotes Long-Term Stabilization of NOXA Protein
2.6. AT101 Primes Cells for Sensitization through NOXA Expression
3. Discussion
4. Materials and Methods
4.1. Cell Culture and Reagents
4.2. Immunoblot Analysis
4.3. Immunoprecipitation Assay
4.4. Chromatin Condensation Assay
4.5. Digitonin Permeabilization (BAD Assay)
4.6. RT-qPCR Analysis
4.7. Cell Transfection and siRNA Knockdown
4.8. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, R.; Letai, A.; Sarosiek, K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 2019, 20, 175. [Google Scholar] [CrossRef] [PubMed]
- Souers, A.J.; Leverson, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J.; Dayton, B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19, 202–208. [Google Scholar] [CrossRef] [PubMed]
- Choudhary, G.S.; Al-harbi, S.; Mazumder, S.; Hill, B.T.; Smith, M.R.; Bodo, J.; Hsi, E.D.; Almasan, A. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015, 6, e1593. [Google Scholar] [CrossRef] [PubMed]
- Wang, Q.; Wan, J.; Zhang, W.; Hao, S. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. Leuk. Lymphoma 2019, 60, 2170–2180. [Google Scholar] [CrossRef] [PubMed]
- Villalobos-Ortiz, M.; Ryan, J.; Mashaka, T.N.; Opferman, J.T.; Letai, A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ. 2020, 27, 999–1007. [Google Scholar] [CrossRef]
- Soderquist, R.S.; Eastman, A. BCL2 inhibitors as anticancer drugs: A plethora of misleading BH3 mimetics. Mol. Cancer Ther. 2016, 15, 2011–2017. [Google Scholar] [CrossRef] [Green Version]
- Castillo, L.; Young, A.I.J.; Mawson, A.; Schafranek, P.; Steinmann, A.M.; Nessem, D.; Parkin, A.; Johns, A.; Chou, A.; Law, A.M.K.; et al. MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. Oncogene 2020, 39, 1821–1829. [Google Scholar] [CrossRef]
- Young, A.I.J.; Law, A.M.K.; Castillo, L.; Chong, S.; Cullen, H.D.; Koehler, M.; Herzog, S.; Brummer, T.; Lee, E.F.; Fairlie, W.D.; et al. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Res. 2016, 18, 125. [Google Scholar] [CrossRef] [Green Version]
- Ding, Q.; He, X.; Xia, W.; Hsu, J.-M.; Chen, C.-T.; Li, L.-Y.; Lee, D.-F.; Yang, J.-Y.; Xie, X.; Liu, J.-C.; et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3β activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007, 67, 4564–4571. [Google Scholar] [CrossRef] [Green Version]
- Caenepeel, S.; Brown, S.P.; Belmontes, B.; Moody, G.; Keegan, K.S.; Chui, D.; Whittington, D.A.; Huang, X.; Poppe, L.; Cheng, A.C.; et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018, 8, 1582–1597. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tron, A.E.; Belmonte, M.A.; Adam, A.; Aquila, B.M.; Boise, L.H.; Chiarparin, E.; Cidado, J.; Embrey, K.J.; Gangl, E.; Gibbons, F.D.; et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 2018, 9, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Kotschy, A.; Szlavik, Z.; Murray, J.; Davidson, J.; Maragno, A.L.; Toumelin-Braizat, G.L.; Chanrion, M.; Kelly, G.L.; Gong, J.-N.; Moujalled, D.M.; et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016, 538, 477–482. [Google Scholar] [CrossRef] [PubMed]
- Fagg, J. Amgen Halts Trials on Cardiac Toxicity. Evaluate Vantage, Posted Online 13 September 2019. Available online: https://www.evaluate.com/vantage/articles/news/snippets/amgen-halts-trials-cardiac-toxicity (accessed on 1 July 2020).
- Wang, X.; Bathina, M.; Lynch, J.; Koss, B.; Calabrese, C.; Frase, S.; Schuetz, J.D.; Rehg, J.E.; Opferman, J.T. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013, 27, 1351–1364. [Google Scholar] [CrossRef] [Green Version]
- Thomas, R.L.; Gustafsson, Å.B. MCL1 is critical for mitochondrial function and autophagy in the heart. Autophagy 2013, 9, 1902–1903. [Google Scholar] [CrossRef] [Green Version]
- Albershardt, T.C.; Salerni, B.L.; Soderquist, R.S.; Bates, D.J.P.; Pletnev, A.A.; Kisselev, A.F.; Eastman, A. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J. Biol. Chem. 2011, 286, 24882–24895. [Google Scholar] [CrossRef] [Green Version]
- Mallick, D.J.; Soderquist, R.S.; Bates, D.; Eastman, A. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477. Cell Death Dis. 2019, 10, 185. [Google Scholar] [CrossRef] [Green Version]
- Soderquist, R.; Bates, D.J.P.; Danilov, A.V.; Eastman, A. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Leukemia 2013, 27, 2262–2264. [Google Scholar] [CrossRef] [Green Version]
- Soderquist, R.; Pletnev, A.A.; Danilov, A.V.; Eastman, A. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA. Apoptosis 2014, 19, 201–209. [Google Scholar] [CrossRef] [Green Version]
- Qian, S.Z.; Wang, Z.G. Gossypol: A potential antifertility agent for males. Annu. Rev. Pharmacol. Toxicol. 1984, 24, 329–360. [Google Scholar] [CrossRef]
- Liu, G.; Kelly, W.K.; Wilding, G.; Leopold, L.; Brill, K.; Somer, B. An Open-Label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 2009, 15, 3172–3176. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meng, Y.; Tang, W.; Dai, Y.; Wu, X.; Liu, M.; Ji, Q.; Ji, M.; Pienta, K.; Lawrence, T.; Xu, L. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol. Cancer Ther. 2008, 7, 2192–2202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stein, M.N.; Goodin, S.; Gounder, M.; Gibbon, D.; Moss, R.; Portal, D.; Lindquist, D.; Zhao, Y.; Takebe, N.; Tan, A.; et al. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Investig. New Drugs 2019, 38, 855–865. [Google Scholar] [CrossRef] [PubMed]
- Soderquist, R.S.; Danilov, A.V.; Eastman, A. Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress. J. Biol. Chem. 2014, 289, 16190–16199. [Google Scholar] [CrossRef] [Green Version]
- Bates, D.; Feris, E.J.; Danilov, A.V.; Eastman, A. Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. Cancer Biol. Ther. 2016, 17, 291–299. [Google Scholar] [CrossRef] [Green Version]
- Parrondo, R.; de las Pozas, A.; Reiner, T.; Perez-Stable, C. ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ 2013, 1, e144. [Google Scholar] [CrossRef] [Green Version]
- Soderquist, R.S.; Crawford, L.; Liu, E.; Lu, M.; Agarwal, A.; Anderson, G.R.; Lin, K.H.; Winter, P.S.; Cakir, M.; Wood, K.C. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. Nat. Commun. 2018, 9, 3513. [Google Scholar] [CrossRef] [Green Version]
- Cho, S.-Y.; Han, J.Y.; Na, D.; Kang, W.; Lee, A.; Kim, J.; Lee, J.; Min, S.; Kang, J.; Chae, J.; et al. A novel combination treatment targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified colorectal cancers. Mol. Cancer Ther. 2017, 16, 2178–2190. [Google Scholar] [CrossRef] [Green Version]
- Wang, Q.; Mora-Jensen, H.; Weniger, M.A.; Perez-Galan, P.; Wolford, C.; Hai, T.; Ron, D.; Chen, W.; Trenkle, W.; Wiestner, A.; et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106, 2200–2205. [Google Scholar] [CrossRef] [Green Version]
- Shibue, T.; Suzuki, S.; Okamoto, H.; Yoshida, H.; Ohba, Y.; Takaoka, A.; Taniguchi, T. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J. 2006, 25, 4952–4962. [Google Scholar] [CrossRef] [Green Version]
- Pang, X.; Zhang, J.; Lopez, H.; Wang, Y.; Li, W.; O’Neill, K.L.; Evans, J.J.D.; George, N.M.; Long, J.; Chen, Y.; et al. The Carboxyl-terminal tail of Noxa protein regulates the stability of Noxa and Mcl-1. J. Biol. Chem. 2014, 289, 17802–17811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Britt, E.L.; Raman, S.; Leek, K.; Sheehy, C.H.; Kim, S.W.; Harada, H. Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment. PLoS ONE 2019, 14, e0219398. [Google Scholar] [CrossRef] [PubMed]
- Okumura, K.; Huang, S.; Sinicrope, F.A. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin. Cancer Res. 2008, 14, 8132–8142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zerp, S.F.; Stoter, T.R.; Hoebers, F.J.P.; van den Brekel, M.W.M.; Dubbelman, R.; Kuipers, G.K.; Lafleur, M.V.M.; Slotman, B.J.; Verheij, M. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: Data from in vitro and clinical pharmacokinetic studies in head and neck cancer. Radiat. Oncol. 2015, 10, 158. [Google Scholar] [CrossRef] [Green Version]
- Potter, D.S.; Letai, A. To prime, or not to prime: That is the question. Cold Spring Harb. Symp. Quant. Biol. 2016, 81, 131–140. [Google Scholar] [CrossRef]
- Liu, Y.; Mondello, P.; Erazo, T.; Tannan, N.B.; Asgari, Z.; de Stanchina, E.; Nanjangud, G.; Seshan, V.E.; Wang, S.; Wendel, H.-G.; et al. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc. Natl. Acad. Sci. USA 2018, 115, 12034–12039. [Google Scholar] [CrossRef] [Green Version]
- Jin, S.; Cojocari, D.; Purkal, J.J.; Popovic, R.; Talaty, N.N.; Xiao, Y.; Solomon, L.R.; Boghaert, E.R.; Leverson, J.D.; Phillips, D.C. 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin. Cancer Res. 2020. [Google Scholar] [CrossRef] [Green Version]
- Fernández, Y.; Verhaegen, M.; Miller, T.P.; Rush, J.L.; Steiner, P.; Opipari, A.W.; Lowe, S.W.; Soengas, M.S. Differential regulation of Noxa in normal melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications. Cancer Res. 2005, 65, 6294–6304. [Google Scholar] [CrossRef] [Green Version]
- Martelli, A.M.; Paganelli, F.; Chiarini, F.; Evangelisti, C.; McCubrey, J.A. The unfolded protein response: A novel therapeutic target in acute leukemias. Cancers 2020, 12, 333. [Google Scholar] [CrossRef] [Green Version]
- Albert, M.-C.; Brinkmann, K.; Kashkar, H. Noxa and cancer therapy. Mol. Cell Oncol. 2014, 1, e29906. [Google Scholar] [CrossRef] [Green Version]
- Djajawi, T.M.; Liu, L.; Gong, J.-N.; Huang, A.S.; Luo, M.-J.; Xu, Z.; Okamoto, T.; Call, M.J.; Huang, D.C.S.; van Delft, M.F. MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1: NOXA complex. Cell Death Differ. 2020. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, Q.; Hu, Z.; Shen, Y.; Jiang, Y.; Pan, P.; Hou, T.; Pan, Z.-Q.; Huang, J.; Sun, Y. Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes. Neoplasia 2020, 22, 179–191. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.; Nikolovska-Coleska, Z.; Yang, C.-Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem. 2006, 49, 6139–6142. [Google Scholar] [CrossRef] [PubMed]
- Bates, D.J.P.; Danilov, A.V.; Lowrey, C.H.; Eastman, A. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Mol. Cancer Ther. 2013, 12, 1504–1514. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schelman, W.R.; Mohammed, T.A.; Traynor, A.M.; Kolesar, J.M.; Marnocha, R.M.; Eickhoff, J.; Keppen, M.; Alberti, D.B.; Wilding, G.; Takebe, N.; et al. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investig. New Drugs 2014, 32, 295–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Z.; Jin, L.; Qian, X.; Wei, M.; Wang, Y.; Wang, J.; Yang, Y.; Xu, Q.; Xu, Y.; Liu, F. Novel Bcl-2 inhibitors: Discovery and mechanism study of small organic apoptosis-inducing agents. ChemBioChem 2007, 8, 113–121. [Google Scholar] [CrossRef] [PubMed]
- Single, B.; Leist, M.; Nicotera, P. Simultaneous release of adenylate kinase and cytochrome c in cell death. Cell Death Differ. 1998, 5, 1001–1003. [Google Scholar] [CrossRef]
- Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic. Acids Res. 2001, 29, e45. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mallick, D.J.; Eastman, A. AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA. Cancers 2020, 12, 2298. https://doi.org/10.3390/cancers12082298
Mallick DJ, Eastman A. AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA. Cancers. 2020; 12(8):2298. https://doi.org/10.3390/cancers12082298
Chicago/Turabian StyleMallick, David J., and Alan Eastman. 2020. "AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA" Cancers 12, no. 8: 2298. https://doi.org/10.3390/cancers12082298